BCRX
- BioCryst Pharmaceuticals, Inc.
()
Overview
Company Summary
BioCryst Pharmaceuticals, Inc. (BCRX) is a biotechnology company that specializes in the discovery, development, and commercialization of novel drugs to combat serious and life-threatening diseases. The company's primary focus is on developing small-molecule drugs that inhibit enzymes involved in diseases caused by an abnormal immune response.
BioCryst develops therapies for diseases such as hereditary angioedema (HAE), a rare genetic disorder that causes recurrent and potentially life-threatening swelling attacks. The company's flagship product for HAE is Orladeyo (berotralstat), an oral medication that helps prevent these attacks.
Additionally, BioCryst is involved in the development of drugs to treat other serious conditions. The company is working on Galidesivir, an antiviral drug with the potential to combat various viral infections, including Ebola and Marburg viruses. It also has programs focused on developing treatments for cystic fibrosis, gout, and other inflammatory disorders.
BioCryst utilizes its expertise in crystallography and structure-based drug design to discover and optimize drug candidates. They conduct preclinical and clinical trials to assess the safety and efficacy of these candidates, seeking approval from regulatory authorities to bring them to the market.
In summary, BioCryst Pharmaceuticals is a biotech company striving to develop innovative therapies for various life-threatening diseases by targeting specific enzymes and utilizing advanced drug discovery techniques.